# Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

> **NCT01561391** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 36 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A With Inhibitors
- Haemophilia B With Inhibitors

## Interventions

- **DRUG:** activated recombinant human factor VII
- **DRUG:** activated recombinant human factor VII
- **OTHER:** factor IX
- **DRUG:** factor VIII

## Key facts

- **NCT ID:** NCT01561391
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** 2004-05
- **Final completion:** 2004-05
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01561391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01561391, "Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01561391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*